LYRA THERAPEUTICS INC (LYRA) Stock News
NASDAQ:LYRA - Nasdaq - US55234L1052 - Common Stock - Currency: USD
LYRA Latest News, Press Relases and Analysis
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
What's going on in today's session
Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
LYRA skyrockets 356% after its lead nasal implant, LYR-210, meets key goals in a pivotal phase III chronic rhinosinusitis study.
Why Lumen Technologies, Inc. (LUMN) Crashed On Wednesday
We recently published a list of Investors Are Dumping These 10 Stocks. In this article, we are going to take a look at where Lumen Technologies, Inc. (NYSE:LUMN) stands against other worst-performing stocks on Wednesday. Lumen Technologies dropped its share prices by 4.87 percent on Wednesday to close at $3.91 apiece after falling 33 spots in […]
Which stocks are moving on Tuesday?
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Lyra Therapeutics Stock Skyrockets On Positive Trial Data For Its Nasal Implant: Retail’s Thrilled
LYR-210 demonstrated statistically significant improvement compared to sham control in key symptoms of chronic rhinosinusitis, such as nasal obstruction, nasal discharge, and facial pain/pressure at week 24.
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)
ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms...
Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
Results from ENLIGHTEN 1 Phase 3 Extension Stage support LYR-210’s favorable safety profile and general consistency with the Primary Study Phase in...
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates
Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of 20% and 23.75%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: DERM
Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
– Phase 3 results from ENLIGHTEN 2 pivotal Phase 3 trial of LYR 210 in Chronic Rhinosinusitis (CRS) expected in Q2 2025 –...
Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates
Vivos Therapeutics (VVOS) delivered earnings and revenue surprises of 34.88% and 5.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Mentions: VVOS
Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025In parallel, the Company...
Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety...
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
-- Topline Results Expected Q2 2025 --
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
WATERTOWN, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology...
LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Beats Revenue for Q2 2024
LYRA stock results show that Lyra Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lyra Therapeutics (NASDAQ:LYRA) just reported results for the second quarter of...
Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
– Primary focus continues to be on upcoming results from ENLIGHTEN 1 Phase 3 extension study in 4Q 2024 and ENLIGHTEN 2 pivotal Phase 3 trial in CRS...
Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital
WATERTOWN, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), today announced that it is advancing...